Optogenetics: Illuminating the Path toward Causal Neuroscience

2019 Warren Alpert Foundation Prize Symposium

In honor of Edward Boyden, Karl Deisseroth, Peter Hegemann, Gero Miesenböck for the development of optogenetics as a way to control the activity of specific circuits in the nervous system, to determine their function and ultimately to control them to treat neurological and psychiatric disorders.

Edward Boyden

Edward Boyden | 2019 Recipient

Edward Boyden is the Y. Eva Tan Professor of Neurotechnology, Professor of Biological Engineering and Brain and Cognitive Sciences at MIT’s Media Lab and McGovern Institute for Brain Research, and Co-Director of the MIT Center for Neurobiological Engineering. In 2018, he was selected to be an Investigator of the Howard Hughes Medical Institute.  While a PhD student at Stanford, he discovered that the molecular mechanisms used to store a memory are determined by the content to be learned. In parallel, he co-invented optogenetic control of neurons. In particular, he and co-winner Karl Deisseroth brainstormed about how microbial opsins could be used to mediate optical control of neural activity while both were students. Together, the two of them collaborated to demonstrate the firstoptical control of neural activity using microbial opsins, with Karl, then a postdoc, and Ed, then a graduate student, performing the gene transfection and the optical stimulation respectively.

His lab at MIT pioneered optogenetic neural silencing using microbial opsins, and further developed the optogenetic toolset towards the neuroscience-driven goals of powerful, noninvasive, high-speed, multiplexed, and single-cell targeted optical control of neural activity. Dr. Boyden has received the Grete Lundbeck Brain Prize (2013), the Jacob Heskel Gabbay Award (2013), the Carnegie Prize in Mind and Brain Sciences (2015), the BBVA Foundation Frontiers of Knowledge Award (2015), the Breakthrough Prize in Life Sciences (2016), and the Canada Gairdner International Award (2018).  He is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Inventors.

Karl Deisseroth

Karl Deisseroth | 2019 Recipient

Deisseroth received his AB from Harvard, MD from Stanford, and PhD from Stanford in 1998. He launched his laboratory spanning the Departments of Bioengineering and Psychiatry at Stanford in July 2004, where he and his students created and developed both optogenetics with microbial opsin genes (a technology to control specific neurons with light), and hydrogel-tissue chemistry (which includes CLARITY, STARmap, and many variants—all allowing the transformation of tissues into optically transparent and tractable hydrogel-hybrid forms suitable for high-resolution structural and molecular study). He was elected to the National Academy of Medicine in 2010, National Academy of Sciences in 2012, and National Academy of Engineering in 2019.Twenty-three alumni from his lab have moved on to tenure-track faculty positions (including Feng Zhang and Ed Boyden, the two students on his initial optogenetics paper).

Deisseroth was the sole recipient (for optogenetics) of the 2010 Koetser Prize, 2010 Nakasone Prize, 2013 Lounsbery Prize, 2014 Dickson Prize in Science, 2015 Keio Prize, 2015 Lurie Prize, 2015 Albany Prize, 2015 Dickson Prize in Medicine, 2017 Redelsheimer Prize, 2017 Fresenius Prize, 2018 Eisenberg Prize, and 2018 Kyoto Prize. For his discoveries, Deisseroth has also received the NIH Director’s Pioneer Award (2005), Zuelch Prize (2012), Perl Prize (2012), BRAIN Prize (2013), Pasarow Prize (2013), Breakthrough Prize (2015), Gabbay Prize (2015), BBVA Award (2016), Massry Prize (2016) and Harvey Prize from the Technion in Israel (2017).

Peter Hegemann

Peter Hegemann | 2019 Recipient

Peter Hegemann is a Hertie professor for neuroscience and head of Experimental Biophysics at Humboldt-Universitaet zu Berlin. Hegemanns research focused almost entirely on the characterization of natural sensory photoreceptors. Hegemann has characterized behavioral and photoelectric responses of the unicellular alga Chlamydomonas, a work that cumulated in the claim that the photoreceptors for these responses a rhodopsins that unify the sensor and ion channel in one protein. He has finally proven this concept by identifying the light gated channel channelrhodopsin, and its functionality in animal cells.

His group characterized this protein in molecular detail by a wide range of biophysical techniques; in close collaboration with Karl Deisseroth this lead to the deciphering of the ion channel mechanism, including gating and ion selection. This work was the basis for the discovery of Optogenetics, a technology where light activated proteins – first of all channelrhodopsin - allow to control selected cells of large networks as the animal brain with unprecedented precision in space and time just by application of light. The Hegemann group also works on light-activated enzymes which further expand the optogenetic applications to important biochemical pathways.

Gero Miesenböck

Gero Miesenböck | 2019 Recipient

Gero Miesenböck is Waynflete Professor of Physiology and founding Director of the Centre for Neural Circuits and Behaviour at the University of Oxford. Before coming to Oxford in 2007, he held faculty appointments at Memorial Sloan-Kettering Cancer Center and Yale University. Miesenböck was the first scientist to modify neurons genetically so that their electrical activity could be controlled with light. This involved inserting DNA for light-responsive opsin proteins into the cells. He used similar genetic modifications to breed animals whose brains contained light-responsive neurons integrated into their circuitry and was the first to demonstrate that the behavior of these animals could be remote-controlled. Miesenböck has received many awards for the invention of optogenetics, including the InBev-Baillet Latour International Health Prize, the Brain Prize, the Heinrich Wieland Prize, the BBVA Foundation Frontiers of Knowledge Award, and the Massry Prize. He is a member of the Austrian and German Academies of Sciences and a Fellow of the Royal Society.

Symposium Program

Each year the recipient(s) of the Warren Alpert Foundation Prize are recognized at a scientific symposium hosted by Harvard Medical School.

Featured Speakers include:

Edward Boyden, PhD

Y. Eva Tan Professor in Neurotechnology MIT Media Lab and McGovern Institute Investigator, Howard Hughes Medical Institute

Karl Deisseroth, MD, PhD

D.H. Chen Professor of Bioengineering and Psychiatry Stanford University Investigator, Howard Hughes Medical Institute

Peter Hegemann, PhD

Hertie Professor for Neuroscience and Head of Experimental Biophysics Humboldt-Universität zu Berlin

Gero Miesenböck, FRS

Waynflete Professor of Physiology and Founding Director of the Centre for Neural Circuits and Behaviour University of Oxford

Invited Speakers Include:

Charlotte Arlt, PhD

Postdoctoral Research Fellow, Department of Neurobiology Harvard Medical School

Kimberly Reinhold, PhD

Postdoctoral Research Fellow, Department of Neurobiology Harvard Medical School

Sign up to receive updates

Sign up to receive updates

Past Symposia

For questions about the prize, please contact us.

Contact Us
I am honored to receive this award in recognition of our seminal work published in Nature in 2011 and in Science in 2012, including the discovery of tracrRNA and the delineation of its key role in the targeting and editing of DNA by CRISPR-Cas9. This work is a wonderful example of the importance of basic research, demonstrating its relevance for translational science and important medical applications.
- Emmanuelle Charpentier

Emmanuelle Charpentier | 2016 Recipient

Emmanuelle Charpentier studied biochemistry, microbiology and genetics at the University Pierre and Marie Curie, Paris, France and obtained her PhD in Microbiology for her research performed at the Pasteur Institute. She then continued her work in the United States, at The Rockefeller University, New York University Langone Medical Center and the Skirball Institute of Biomolecular Medicine (all in New York, NY) and at St Jude Children's Research Hospital (in Memphis, TN). E. Charpentier returned to Europe to establish her own research group at the Max F. Perutz Laboratories of the University of Vienna in Austria where she habilitated in the field of Microbiology. She was then appointed Associate Professor at the Laboratory for Molecular Infection Medicine Sweden (MIMS, part of Nordic European Molecular Biology Laboratory (EMBL) Partnership for Molecular Medicine) at Umeå University in Sweden where she habilitated in the field of Medical Microbiology and is still active as a Visiting Professor. Between 2013 and 2015, E. Charpentier was Head of the Department of Regulation in Infection Biology at the Helmholtz Centre for Infection Research, Braunschweig, and Professor at the Medical School of Hannover in Germany. In 2013, she was awarded an Alexander von Humboldt Professorship, which she has held since 2014. In 2015, E. Charpentier was appointed Scientific Member of the Max Planck Society in Germany and Director at the Max Planck Institute for Infection Biology in Berlin, Germany.

E. Charpentier is recognized as a world-leading expert in regulatory mechanisms underlying processes of infection and immunity in bacterial pathogens. Her work has led to a number of seminal discoveries and insights into pathways governing antibiotic resistance and virulence of bacterial pathogens. With her recent groundbreaking findings in the field of RNA-mediated regulation based on the CRISPR-Cas9 system, E. Charpentier has laid the foundation for the development of a novel, highly versatile and specific genome editing technology that is revolutionizing life sciences research and could open up whole new opportunities in biomedical gene therapies. The resulting field of research is now developing at dazzling speed, with exciting new aspects emerging almost weekly. E. Charpentier is Elected Foreign Member of The Royal Swedish Academy of Sciences 2015, Elected Member German National Academy of Sciences 2015, Elected Member of the European Academy of Microbiology 2015, Elected Fellow of the American Academy of Microbiology in 2015 and Elected EMBO Member in 2014. E. Charpentier has been awarded prestigious honors including the Paul Ehrlich and Ludwig Darmstaedter Prize 2016, French Chevalier Order de la Légion d’Honneur in 2016, World Technology Award for Biotechnology 2015, Leibniz Prize 2016, a 2016 Vallee Visiting Professorship, the 2016 HFSP Nakasone Award, an Honorary Doctorate of the KU Leuven, the Science Award of Lower Saxony 2015, the ABRF Annual Award for Outstanding Contributions to Biomolecular Technologies 2016, the Massry Prize 2015, the Otto Warburg Medal 2016, the L’Oréal-UNESCO For Women in Science Award 2016, the Carus-Medal of the German National Academy of Sciences Leopoldina 2015, the Umeå University EC Jubilee Award in 2015, the Gruber Prize in Genetics 2015, the Princess of Asturias Award for Technical and Scientific Research 2015, the 11th International Society for Transgenic Technologies Prize, the Hansen Family Award 2015, the 2015 Louis Jeantet Prize for Medicine, the 2015 Ernst Jung Prize for Medicine, the 2015 Breakthrough Prize in Life Sciences, the 2014 Grand Prix Jean-Pierre LeCocq, the 2014 Jacob Heskel Gabbay Award in Biotechnology and Medicine, the 2014 Dr Paul Janssen Award, the 2014 Göran Gustafsson Prize, an Alexander von Humboldt Professorship in 2013 and the Eric K. Fernström Prize in 2011. The impact of her scientific accomplishments has also been recognized in the broader community of world affairs. E. Charpentier was selected as one of TIME’s 100 Most Influential People in the World in 2015, one of Foreign Policy’s 100 Leading Global Thinkers in 2014, one of Vanity Fair’s 50 most influential French people worldwide in 2014.

E. Charpentier is inventor and co-owner of seminal intellectual property comprising the CRISPR-Cas9 technology, and co-founder of CRISPR Therapeutics and ERS Genomics, created to facilitate the development of the CRISPR-Cas9 genome engineering technology for biotechnological and biomedical purposes.

(2016-03-06) picture: “Hallbauer&Fioretti”

View Past Recipients